TR201904388T4 - Pregabalin veya gabapentin ve 3-(3-dimetilamino-1-etil-2-metil-propil)-fenolün farmasötik kombinasyonu. - Google Patents

Pregabalin veya gabapentin ve 3-(3-dimetilamino-1-etil-2-metil-propil)-fenolün farmasötik kombinasyonu. Download PDF

Info

Publication number
TR201904388T4
TR201904388T4 TR2019/04388T TR201904388T TR201904388T4 TR 201904388 T4 TR201904388 T4 TR 201904388T4 TR 2019/04388 T TR2019/04388 T TR 2019/04388T TR 201904388 T TR201904388 T TR 201904388T TR 201904388 T4 TR201904388 T4 TR 201904388T4
Authority
TR
Turkey
Prior art keywords
dimethylamino
propyl
ethyl
methyl
phenol
Prior art date
Application number
TR2019/04388T
Other languages
English (en)
Inventor
Schiene Klaus
Bloms-Funke Petra
Christoph Thomas
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40345058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201904388(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of TR201904388T4 publication Critical patent/TR201904388T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Mevcut buluş, (a) en az bir 3-(3-Dimetilamino-1-etil-2-metil-propil)-fenol bileşiği ve (b) en az bir antiepileptik, farmasötik bir formülasyon ve söz konusu kombinasyonu içeren bir dozaj formunun yanı sıra, örneğin nöropatik ağrı gibi ağrı tedavisine yönelik bir yöntem ile ilgilidir, burada (a) ve (b) bileşenleri, bir memeliye aynı anda veya sırayla uygulanır, burada (a) bileşeni, (b) bileşeninden önce veya sonra uygulanabilir, burada (a) veya (b) bileşenleri, memeliye aynı veya farklı bir uygulama yolu vasıtasıyla uygulanır.
TR2019/04388T 2008-09-05 2009-09-04 Pregabalin veya gabapentin ve 3-(3-dimetilamino-1-etil-2-metil-propil)-fenolün farmasötik kombinasyonu. TR201904388T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08015625 2008-09-05

Publications (1)

Publication Number Publication Date
TR201904388T4 true TR201904388T4 (tr) 2019-05-21

Family

ID=40345058

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/04388T TR201904388T4 (tr) 2008-09-05 2009-09-04 Pregabalin veya gabapentin ve 3-(3-dimetilamino-1-etil-2-metil-propil)-fenolün farmasötik kombinasyonu.

Country Status (28)

Country Link
US (1) US20100063148A1 (tr)
EP (2) EP2331210B1 (tr)
JP (4) JP5731387B2 (tr)
KR (3) KR101851120B1 (tr)
CN (2) CN105520924B (tr)
AR (2) AR073361A1 (tr)
AU (3) AU2009289776A1 (tr)
BR (1) BRPI0920521A2 (tr)
CA (1) CA2735857C (tr)
CL (1) CL2011000317A1 (tr)
CO (1) CO6382142A2 (tr)
CY (2) CY1115751T1 (tr)
DK (2) DK2735338T3 (tr)
EC (1) ECSP11010869A (tr)
ES (2) ES2513394T3 (tr)
HR (2) HRP20140663T1 (tr)
HU (1) HUE043278T2 (tr)
IL (3) IL211135A (tr)
LT (1) LT2735338T (tr)
MX (1) MX2011002339A (tr)
PE (5) PE20190914A1 (tr)
PL (2) PL2331210T3 (tr)
PT (2) PT2735338T (tr)
RU (2) RU2571501C2 (tr)
SI (2) SI2735338T1 (tr)
TR (1) TR201904388T4 (tr)
WO (1) WO2010025931A2 (tr)
ZA (1) ZA201101449B (tr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
EA019757B1 (ru) * 2006-06-15 2014-06-30 ЮСиБи ФАРМА ГМБХ Фармацевтическая композиция с синергетическим противосудорожным эффектом
SI2735338T1 (sl) * 2008-09-05 2019-04-30 Grunenthal Gmbh Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol in pregabalina ali gabapentina
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
FR2943246B1 (fr) * 2009-03-19 2011-07-29 Biocodex Compose pour son utilisation dans le traitement des neuropathies peripheriques
SI2582366T1 (sl) 2010-06-15 2016-02-29 Gruenenthal Gmbh Farmacevtska kombinacija za zdravljenje bolečine
AR082189A1 (es) 2010-07-06 2012-11-21 Gruenenthal Gmbh Formas de dosificacion gastrorretentivas, procedimiento
CA2805371C (en) 2010-07-30 2017-10-31 Toray Industries, Inc. Therapeutic agent or prophylactic agent for neuropathic pain
CA2828635C (en) * 2011-03-04 2020-01-14 Grunenthal Gmbh Parenteral administration of tapentadol
EP2753302B1 (en) * 2011-07-20 2018-11-28 Torrent Pharmaceuticals Ltd. Pharmaceutical composition of tapentadol
EP2736501B1 (en) * 2011-07-29 2017-12-20 Grünenthal GmbH Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US8912226B2 (en) * 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US9320725B2 (en) * 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US20130310435A1 (en) * 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
BR112015009839A2 (pt) * 2012-11-01 2017-07-11 Torrent Pharmaceuticals Ltd composição farmacêutica de tapentadol para administração parenteral
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
PT4293009T (pt) 2015-12-22 2025-09-08 Zogenix International Ltd Composições de fenfluramina e métodos de preparação das mesmas
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
AU2017315273B2 (en) * 2016-08-24 2021-04-29 Zogenix International Limited Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
KR20190081385A (ko) 2017-12-29 2019-07-09 강원대학교산학협력단 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
AU2019384963B2 (en) 2018-11-19 2022-05-26 Zogenix International Limited Methods of treating Rett syndrome using fenfluramine
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
HUP0203198A3 (en) 1999-08-20 2005-07-28 Ortho Mcneil Pharm Inc Pharmaceutical composition comprising a tramadol material and an anticonvulsant drug, process for its preparation and its use
EP1471909A4 (en) * 2002-01-16 2007-07-25 Endo Pharmaceuticals Inc PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
RU2286151C2 (ru) * 2002-02-22 2006-10-27 Уорнер-Ламберт Компани Ллс Комбинации альфа-2-дельта-лиганда с селективным ингибитором циклооксигеназы-2
WO2007005716A2 (en) * 2005-06-30 2007-01-11 Cinergen, Llc Methods of treatment and compositions for use thereof
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
CN105561311B (zh) * 2006-04-28 2019-07-16 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和nsaid的药物组合物
WO2008027442A2 (en) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
CN102908339A (zh) * 2007-11-23 2013-02-06 格吕伦塔尔有限公司 他喷他多组合物
CA2706575C (en) * 2008-01-25 2015-07-14 Xenoport, Inc. Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs
SI2735338T1 (sl) * 2008-09-05 2019-04-30 Grunenthal Gmbh Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol in pregabalina ali gabapentina

Also Published As

Publication number Publication date
PL2735338T3 (pl) 2019-07-31
ES2513394T3 (es) 2014-10-27
EP2735338B1 (en) 2019-02-06
PE20110291A1 (es) 2011-06-04
PE20190914A1 (es) 2019-06-26
RU2674150C1 (ru) 2018-12-05
PT2331210E (pt) 2014-08-25
IL237392B (en) 2019-08-29
AR073361A1 (es) 2010-11-03
CL2011000317A1 (es) 2011-06-17
SI2735338T1 (sl) 2019-04-30
RU2011112444A (ru) 2012-10-10
JP2015096530A (ja) 2015-05-21
EP2331210B1 (en) 2014-07-09
WO2010025931A2 (en) 2010-03-11
KR20110057144A (ko) 2011-05-31
SI2331210T1 (sl) 2014-10-30
IL237392A0 (en) 2015-04-30
AU2016203053B2 (en) 2018-01-25
CA2735857C (en) 2019-05-28
PE20142357A1 (es) 2015-02-04
US20100063148A1 (en) 2010-03-11
AU2018202879A1 (en) 2018-05-17
RU2571501C2 (ru) 2015-12-20
CO6382142A2 (es) 2012-02-15
DK2735338T3 (en) 2019-04-23
JP5731387B2 (ja) 2015-06-10
ES2719900T3 (es) 2019-07-16
KR20170048602A (ko) 2017-05-08
KR101641519B1 (ko) 2016-07-21
CA2735857A1 (en) 2010-03-11
CN102159284A (zh) 2011-08-17
CY1121492T1 (el) 2020-05-29
MX2011002339A (es) 2011-04-04
CY1115751T1 (el) 2017-01-25
EP2331210A2 (en) 2011-06-15
IL237391A0 (en) 2015-04-30
CN105520924A (zh) 2016-04-27
DK2331210T3 (da) 2014-08-11
HRP20190500T1 (hr) 2019-08-09
AR117613A2 (es) 2021-08-18
HRP20140663T1 (hr) 2014-10-10
KR101730924B1 (ko) 2017-04-27
HK1159011A1 (en) 2012-07-27
JP2017071636A (ja) 2017-04-13
EP2735338A1 (en) 2014-05-28
AU2016203053A1 (en) 2016-06-02
PT2735338T (pt) 2019-05-24
ZA201101449B (en) 2011-10-26
IL237391A (en) 2017-12-31
AU2018202879B2 (en) 2020-03-12
KR101851120B1 (ko) 2018-04-23
LT2735338T (lt) 2019-04-10
WO2010025931A3 (en) 2010-06-17
HUE043278T2 (hu) 2019-08-28
HK1198145A1 (en) 2015-03-13
AU2009289776A1 (en) 2010-03-11
BRPI0920521A2 (pt) 2018-01-16
PE20142371A1 (es) 2015-02-04
PE20142372A1 (es) 2015-02-04
IL211135A (en) 2017-09-28
CN102159284B (zh) 2015-12-09
ECSP11010869A (es) 2011-04-29
PL2331210T3 (pl) 2014-12-31
JP2012501986A (ja) 2012-01-26
KR20160086981A (ko) 2016-07-20
CN105520924B (zh) 2019-04-09
JP2019131578A (ja) 2019-08-08
IL211135A0 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
TR201904388T4 (tr) Pregabalin veya gabapentin ve 3-(3-dimetilamino-1-etil-2-metil-propil)-fenolün farmasötik kombinasyonu.
AU2016219643A1 (en) Pharmaceutical combination for the treatment of pain
ECSP12011787A (es) Polipéptidos para unión al "receptor para productos finales de glicosilación avanzada" así como composiciones y métodos que implican a los mismos
ECSP17000643A (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.
ECSP088873A (es) Combinación farmaceutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil) fenol y nsaid
EA201070421A1 (ru) Микрорибонуклеиновые кислоты
EA201290919A1 (ru) Индазольные соединения и их применение
MX349992B (es) Composiciones de alta concentracion de alfa-glucosidasa para el tratamiento de la enfermedad de pompe.
PE20141672A1 (es) FORMULACION PARA ANTICUERPO ANTI-alfa4�7
UA98623C2 (ru) Соединения диосметина, способ их получения и фармацевтическая композиция, которая их содержит
BR112013004865A2 (pt) lípidos adequados para entrega lipossomal de codificadores de proteínas rna
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
EA201390840A1 (ru) Полициклический lpaантагонист и его применение
BR112014015568A8 (pt) compostos carbamato de fenila para uso em prevenção ou tratamento de epilepsia
EA201201298A1 (ru) Фунгицидные композиции, содержащие фосфорастворимый микроорганизм и фунгицидно активное соединение
UA111357C2 (uk) Аналоги епоксіейкозатриєнової кислоти, композиція на їх основі, застосування для лікування захворювань та спосіб зниження гіпертонії та нефротоксичності (варіанти)
DOP2014000300A (es) Composiciones farmacéuticas y tratamiento de mastitis
EA201490395A1 (ru) Способ получения фармацевтических композиций, содержащих финголимод
AR086395A1 (es) Envase para el tratamiento de patologias
BR122020011180B8 (pt) formulações injetáveis de compostos de tetraciclina
BRPI0814115B8 (pt) composição farmacêutica compreendendo o composto 11-deóxi-prostaglandina e método para estabilizar o composto
EA201390844A1 (ru) Комплексный состав, содержащий гидрохлорид лерканидипина и валсартан, и способ его получения
ECSP11010876A (es) Combinación farmacéutica que contiene el 6-dimetilaminometil-1-(3-metoxi-fenil)-ciclohexano-1,3-diol y paracetamol
UY33487A (es) ?(3-(4-(aminometil)fenoxi o feniltio)azetidin-1-il)(5-fenil-1,3,4-oxadiazol- 2-il)metanona?.
BRPI0601496A (pt) composições medicamentosas, uso das mesmas, kits medicamentosos e método de aplicação das composições medicamentosas